ASTEC · Astec LifeSciences Ltd · Chemical Manufacturing
ASTEC · Astec LifeSciences Ltd · Chemical Manufacturing
As of 05 Nov close
52-week range
40.4% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹84 Cr
Revenue YoY
PAT YoY
+43.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
4.1
P/S (TTM)
3.5
Sector P/E
20.6
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ASTEC (this stock) | Not meaningful (earnings negative over the last 12 months) | 4.1 | -15.1% | -17.1% | 1.15 | 0.0% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Solar Industries India | 102.6 | 27.4 | +17.6% | +31.4% | 13.68 | +0.1% |
| Pidilite Industries | 61.3 | 19.4 | +17.2% | +24.4% | 0.04 | +0.7% |
Promoter
stable
FII
stable
MF
3.02% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-09 | ASTEC | 993527 | 5 | WEAK | BULK |
| 2026-05-18 | ASTEC | 121381 | 1 | WEAK | BULK |
News timeline
- lowbusiness-standard.com· 26 Oct 2026, 10:16 amQ2 results: Paytm, REC, Tata Consumer Products among 98 firms on October 26
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAstec LifeSciences Limited (ASTEC) reported consolidated total income of ₹235 crore for FY2025-26, with a strong parentage under Godrej Industries Group. The company operates in 19 countries, focusing on specialty molecules, triazole fungicides, and contract manufacturing (CDMO). Key audit matters included revenue recognition risks, with auditors verifying controls and documentation. The company has no defaults in loan repayments or statutory dues, though some tax disputes are pending. Management highlights global macroeconomic volatility and supply chain disruptions as challenges.
- Consolidated total income of ₹235 crore in FY2025-26.
- No defaults in loan repayments or statutory dues.
- Pending tax disputes under various acts (Income Tax, Central Excise, GST) with amounts disputed but not in default.
- Key audit focus on revenue recognition controls and documentation.
- Operational in 19 countries with emphasis on specialty chemicals and CDMO services.
Key takeaway: Astec LifeSciences reported strong financials with no defaults but faces pending tax disputes and global operational risks.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company was fined ₹2,59,600 each by NSE and BSE for non-compliance with the Listing Regulations regarding the appointment of an independent director.
Default / Covenant Breach
2 occurrencesEarlier (1-3 years ago)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2024, including Income Tax, Excise Duty, and Sales Tax, with amounts totaling over 5,000 lakhs across various periods and forums.
Older (3+ years ago)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2022, including Income Tax amounts totaling ₹340.79 lakh for FY 2016-17, with disputes pending before the CIT (A) and other authorities.
Routine disclosures
Contingent Liability
4 occurrencesRecent (last 12 months)
The company has contingent liabilities related to excise duty, customs, GST, income tax, and sales tax matters, including pending appeals and demands with interest, as well as guarantees and letters of credit.
Earlier (1-3 years ago)
The company has a contingent liability related to share-based payment transactions, with expenses recognized in the profit or loss as part of employee benefit expenses for the years ending March 31, 2024 and March 31, 2023.
Older (3+ years ago)
ASTEC LIFESCIENCES LIMITED has pending litigations under various laws such as Income Tax, Excise, VAT, Customs and GST as of 31 March 2023.
The company has pending litigations under various laws such as Income Tax, Excise, VAT, Customs and GST as of 31 March 2022.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company entered into related party transactions with Godrej Agrovet Limited (its Holding Company) during FY2025-26, with an aggregate limit of up to ₹400 Crore, approved by members via an ordinary resolution through postal ballot.
Older (3+ years ago)
The company conducted transactions with related parties including Godrej Agrovet Limited (holding company) and Godrej Consumer Products Limited (other related party) involving sale and purchase of materials, finished goods, and property, plant & equipment.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has statutory dues disputes with various authorities, including Income Tax, Excise Duty, and Goods & Service Tax, with amounts demanded and paid under protest, and disputes pending before various forums.
Older (3+ years ago)
The company has statutory dues pending in disputes, including Goods and Services Tax, Provident Fund, Employees' State Insurance, Income-Tax, Duty of Customs, or Cess, with amounts and the forum where disputes are pending listed.
Management & Board Governance
2 occurrencesRecent (last 12 months)
The Chief Financial Officer, Ms. Mugdha Amol Khare, resigned with effect from the close of business hours on March 31, 2026.
Earlier (1-3 years ago)
Mr. K. Suryanarayan, the Chief Financial Officer, resigned with effect from close of business hours on 3rd May, 2024.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.75% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).